Kerry-Anne Rye

Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells.

Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling.

Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits.

Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation.

Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I.

Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids.

Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux.

High-density lipoproteins neutralize C-reactive protein proinflammatory activity.

Apolipoproteins regulate the kinetics of endothelial lipase-mediated hydrolysis of phospholipids in reconstituted high-density lipoproteins.

Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner.

Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation.

Antiinflammatory properties of HDL.

Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits.

Apolipoprotein E activates the low-activity form of human phospholipid transfer protein.

Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro.

High-density lipoproteins as therapeutic targets.

Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity.

Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits.

Inhibition of H-Ras and MAPK is compensated by PKC-dependent pathways in annexin A6 expressing cells.

Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit.

What is so special about apolipoprotein AI in reverse cholesterol transport?

ApoA-I/phosphatidylcholine discs remodels fast-migrating HDL into slow-migrating HDL as characterized by capillary isotachophoresis.

ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I.

High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics.

Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E.

High-density lipoproteins enhance progenitor-mediated endothelium repair in mice.

Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?

Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.

Are we lowering LDL cholesterol sufficiently?

Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis.

Relationship between the concentration and antiatherogenic activity of high-density lipoproteins.

Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function.

Homocysteine and cardiovascular disease: is HDL the link?

Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.

Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation.

Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo.

Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation.

Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration.

Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis.

Effects of reconstituted HDL on charge-based LDL subfractions as characterized by capillary isotachophoresis.

N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins.

POPC/apoA-I discs as a potent lipoprotein modulator in Tangier disease.

Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo.

Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels.

Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.

Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein.

Analysis of apolipoprotein E nuclear localization using green fluorescent protein and biotinylation approaches.

Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice.

New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Antiarrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats.

ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro.

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice.

Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats.

Molecular basis of PCSK9 function.

Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes.

Antiinflammatory actions of HDL: a new insight.

The metabolism and anti-atherogenic properties of HDL.

High-density lipoproteins, inflammation and oxidative stress.

Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I.

Isoform-specific proteolysis of apolipoprotein-E in the brain.

Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.

Cholesterol metabolism and pancreatic beta-cell function.

Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts.

Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.

Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?

HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis.

The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids.

Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion.

Pharmacological intervention using reconstituted high-density lipoprotein changes in the lipid profile in spontaneously hypersensitive rats.

Anti-inflammatory effects of apolipoprotein A-I in the rabbit.

High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo.

Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy.

The low resolution structure of ApoA1 in spherical high density lipoprotein revealed by small angle neutron scattering.

Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages.

Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I.

Ras/mitogen-activated protein kinase (MAPK) signaling modulates protein stability and cell surface expression of scavenger receptor SR-BI.

The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins.

Possibility of increasing cholesterol efflux by adiponectin and its receptors through the ATP binding cassette transporter A1 in HEK293T cells.

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Identification of an amino acid residue in ATP-binding cassette transport G1 critical for mediating cholesterol efflux.

Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008.

Predictive value of different HDL particles for the protection against or risk of coronary heart disease.

Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?

Niacin inhibits vascular inflammation via the induction of heme oxygenase-1.

The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit.

The emerging role of HDL in glucose metabolism.

Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein.

ApoA-1 infusion reduces arterial cholesterol and myocardial lesions in a rat model of cardiac dysfunction and insulin resistance.

The inhibition of cholesteryl ester transfer protein: a long and winding road.

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.

Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.

Phenotypic and functional changes in blood monocytes following adherence to endothelium.

Relationship between atorvastatin dose and the harm caused by torcetrapib.

Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl).

High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-Δ24 reductase expression and inducing heme oxygenase-1.

Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.

Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008.

High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells.

Dietary sphingomyelin lowers hepatic lipid levels and inhibits intestinal cholesterol absorption in high-fat-fed mice.

Inhibition of mitogen-activated protein kinase Erk1/2 promotes protein degradation of ATP binding cassette transporters A1 and G1 in CHO and HuH7 cells.

Trends in C-reactive protein levels in US adults from 1999 to 2010.

Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages.

High density lipoprotein structure, function, and metabolism: a new Thematic Series.

Cardioprotective functions of HDLs.

Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease.

MicroRNAs in the onset and development of cardiovascular disease.

Cardiovascular risk, lipids and pregnancy: preeclampsia and the risk of later life cardiovascular disease.

High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation.

Inhibition of arthritis in the Lewis rat by apolipoprotein A-I and reconstituted high-density lipoproteins.

Regulation of high-density lipoprotein metabolism.

HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells.

Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.

Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).

The relationship between total bilirubin levels and total mortality in older adults: the United States National Health and Nutrition Examination Survey (NHANES) 1999-2004.

The relationship between insulin resistance and vascular calcification in coronary arteries, and the thoracic and abdominal aorta: the Multi-Ethnic Study of Atherosclerosis.

Apolipoprotein A-I increases insulin secretion and production from pancreatic β-cells via a G-protein-cAMP-PKA-FoxO1-dependent mechanism.

MicroRNA-223 coordinates cholesterol homeostasis.

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.

Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.

HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export.

Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.

Relationship of pericardial fat with biomarkers of inflammation and hemostasis, and cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis.

HDL surface lipids mediate CETP binding as revealed by electron microscopy and molecular dynamics simulation.

HDL function as a predictor of coronary heart disease events: time to re-assess the HDL hypothesis?

Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.

The impact of LDLR function on fibroblast growth factor 21 levels.

Relationship of pericardial fat with lipoprotein distribution: The Multi-Ethnic study of atherosclerosis.

Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.

Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.

Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis.

Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?

Speed kills in more ways than one: Methamphetamine and atherosclerosis.

Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?

Apolipoprotein A-I interactions with insulin secretion and production.

Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead--Pro.

A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo.

High-Density Lipoprotein-Associated miR-223 Is Altered after Diet-Induced Weight Loss in Overweight and Obese Males.

Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I.

New Era of Lipid-Lowering Drugs.

Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo.

Coronary artery disease: Scavenger receptor class B1--a target to reduce CHD risk?

Lipidology, cardiovascular risk, and schizophrenia.

Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.

Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial.

In vivo PET imaging with [(18)F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes.

Glycated albumin induces lipid infiltration in mice aorta independently of DM and RAS local modulation by inducing lipid peroxidation and inflammation.

Human macrophage cathepsin B-mediated C-terminal cleavage of apolipoprotein A-I at Ser228 severely impairs antiatherogenic capacity.

Cholesterol efflux capacity: An introduction for clinicians.

Impact of Perturbed Pancreatic β-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism.

The protective effect of apolipoprotein in models of trophoblast invasion and preeclampsia.

High-Density Lipoproteins Exert Pro-inflammatory Effects on Macrophages via Passive Cholesterol Depletion and PKC-NF-κB/STAT1-IRF1 Signaling.

Erratum. Impact of Perturbed Pancreatic β-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism. Diabetes 2016;65:3610-3620.

The role of fibroblast growth factor 21 in atherosclerosis.

The ATP binding cassette transporter, ABCG1, localizes to cortical actin filaments.